Author Archives: Patricia Inacio PhD

Vercise Genus, 4th-generation DBS Treatment, Coming Soon to US

Vercise Genus, a fourth-generation system for deep brain stimulation (DBS) to treat people with Parkinson’s disease, is now available in the U.S.,  Boston Scientific, which markets the system, announced. The U.S. Food and Drug Administration approved the system’s conditional use with full-body MRI scans, following a similar…

Spiroco 4mg Prolonged-release XL Tablets Discontinued

Teva has discontinued Spiroco (ropinirole) 4mg XL prolonged-release tablets due to factors out of the company’s control, according to an announcement from Parkinson’s UK. The company — which outside the U.S. manufactures ropinirole XL as a generic formulation in three concentrations — is still marketing Spiroco…

FDA to Review Nuplazid as Treatment for Dementia-related Psychosis

The U.S. Food and Drug Administration (FDA) will review Acadia Pharmaceutical’s application asking that Nuplazid (pimavanserin) also be approved to treat hallucinations and delusions associated with various forms of dementia-related psychosis, the company announced. The supplemental new drug application (sNDA) was granted standard review status, and the…